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Abstract
Background—Conventional benzodiazepines bind non-selectively to GABAA receptors 
containing α1, α2, α3, and α5 subunits (α1GABAA, α2GABAA, α3GABAA, and α5GABAA 
receptors, respectively), and the role of these different GABAA receptor subtypes in the 
reinforcing effects of benzodiazepines has not been characterized fully. We used a 
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pharmacological antagonist approach with available subtype-selective ligands to evaluate the role 
of GABAA receptor subtypes in the reinforcing effects of the non-selective conventional 
benzodiazepine, triazolam.
Methods—Rhesus monkeys (n = 4) were trained under a progressive-ratio schedule of 
intravenous midazolam delivery and dose–response functions were determined for triazolam, in 
the absence and presence of flumazenil (non-selective antagonist), βCCT and 3-PBC (α1GABAA-
preferring antagonists), and XLi-093 (α5GABAA-selective antagonist).
Results—Flumazenil, βCCT and 3-PBC shifted the dose–response functions for triazolam to the 
right in a surmountable fashion, whereas XLi-093 was ineffective. Schild analyses revealed rank 
orders of potencies of flumazenil = βCCT > 3-PBC. Comparison of potencies between self-
administration and previous binding studies with human cloned GABAA receptor subtypes 
suggested that the potencies for βCCT and 3-PBC were most consistent with binding at 
α2GABAA and α3GABAA receptors, but not α1GABAA or α5GABAA receptor subtypes.
Conclusions—Our findings were not entirely consistent with blockade of α1GABAA receptors 
and are consistent with the possibility of α2GABAA and/or α3GABAA subtype involvement in 
antagonism of the reinforcing effects of triazolam. The α5GABAA receptor subtype likely does 
not play a substantial role in self-administration under these conditions.
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1. Introduction
Benzodiazepines bind to an allosteric site on γ-aminobutyric acid type A (GABAA) 
receptors, producing a conformational change in the receptor leading to an enhancement in 
the ability of GABA to increase chloride conductance. It is through this receptor mechanism 
that benzodiazepines produce behavioral effects that can be beneficial therapeutically (e.g., 
anxiolysis). These same receptors also mediate other characteristic effects that limit the use 
of benzodiazepines, such as daytime drowsiness, impairment of motor coordination, and 
deficits in memory (for review, see Rudolph and Knoflach, 2011). In addition and perhaps 
of most concern is that benzodiazepines have reinforcing properties that may contribute to 
their having abuse liability (Griffiths and Weerts, 1997; Licata and Rowlett, 2008).
Previous molecular biological studies have revealed the existence of multiple subtypes of 
the GABAA receptor (McKernan and Whiting, 1996; Olsen and Sieghart, 2008; Pritchett et 
al., 1989; Rudolph et al., 2001). Subsequent reports have postulated that the diverse 
behavioral effects of benzodiazepine-type drugs may reflect actions at different subtypes of 
GABAA receptors (e.g., Knabl et al., 2008; Löw et al., 2000; McKernan et al., 2000; 
Rowlett et al., 2005; Rudolph et al., 1999; Tan et al., 2010). These observations suggest the 
possibility for a pharmacological dissociation between the clinically advantageous effects 
and unwanted side-effects of these compounds.
Most benzodiazepine ligands bind to GABAA receptors containing α1, α2, α3, and α5 
subunits, but not α4 and α6 subunits (Rudolph and Knoflach, 2011). GABAA receptors 
Fischer et al. Page 2
Drug Alcohol Depend. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
containing α1 subunits (α1GABAA receptors) are located ubiquitously throughout the CNS, 
and have been implicated in the sedative effects of benzodiazepines as well as in effects 
related to physical dependence and abuse (Engin et al., 2014; Fischer et al., 2013; Mirza and 
Nielsen, 2006; Rudolph et al., 1999; Tan et al., 2010). In contrast, GABAA receptors 
containing α2 and α3 subunits (α2GABAA and α3GABAA receptors, respectively) are 
anatomically distributed in the cortex, limbic system and spinal cord (Rudolph and 
Knoflach, 2011) and have been associated with the anxiolytic effects of benzodiazepines 
(Fischer et al., 2010; Löw et al., 2000; McKernan et al., 2000; Rowlett et al., 2005). Finally, 
GABAA receptors containing α5 subunits (α5GABAA receptors) are preferentially 
expressed within the hippocampus and are thought to play a role in certain memory 
processes impacted by benzodiazepines (Atack, 2011; Collinson et al., 2002; Crestani et al., 
2002).
The precise roles of α1GABAA, α2GABAA, α3GABAA and α5GABAA receptors in the 
reinforcing properties of benzodiazepines are unclear at present. A recent hypothesis 
suggests that α1GABAA receptors, specifically those expressed in the ventral tegmental 
area, underpin the reinforcing properties of benzodiazepines (Tan et al., 2011). According to 
Tan et al. (2011), benzodiazepines are proposed to decrease activity of GABAergic 
interneurons through activation of α1GABAA receptors, resulting in a disinhibition of 
dopaminergic signaling and a net increase of dopamine release in the nucleus accumbens. 
This hypothesis is consistent with the finding that benzodiazepines are not self-administered 
in mice rendered benzodiazepine-insensitive at α1GABAA receptors (Engin et al., 2014; Tan 
et al., 2010), and the observation that baboons do not self-administer the α1GABAA 
receptor-sparing (i.e., low-to-zero intrinsic efficacy at α1GABAA receptors) compound 
TPA023 up to doses that maximally occupy CNS benzodiazepine binding sites (Ator et al., 
2010). However, we have demonstrated that α1GABAA receptor-sparing compounds are 
reliably self-administered in rhesus monkeys trained with GABAA positive modulators 
(midazolam, methohexital) but not the monoamine transport blocker cocaine (Rowlett et al., 
2005; Shinday et al., 2013). Overall, these findings suggest that α1GABAA receptors are 
critical for the reinforcing effects of benzodiazepines only under certain conditions (e.g., 
history of cocaine exposure), but are not necessary for a benzodiazepine to have reinforcing 
effects when the monkeys are experienced with a GABAA positive modulator. The 
relevance of this observation to human drug abusers is unclear at present, although 
considerable literature suggests that a human subject’s prior drug experiences are predictors 
of benzodiazepine consumption (for review, see Griffiths and Weerts, 1997).
In the present study, a pharmacological-antagonist approach was used to assess further the 
role of GABAA receptors containing different subunits in the reinforcing effects of 
benzodiazepines. Rhesus monkeys were trained to self-administer the non-selective 
benzodiazepine midazolam under a progressive ratio (PR) schedule of reinforcement. For 
antagonism studies, we chose the short-acting, non-selective triazolobenzodiazepine 
triazolam, which readily maintains self-administration in monkeys in our hands (e.g., 
Fischer and Rowlett, 2011). Dose–response determinations of triazolam were obtained and 
then re-assessed following the administration of a non-selective or a selective 
benzodiazepine receptor antagonist. At present, GABAA receptor subtype selective 
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antagonists are available that show preferential binding at α1GABAA receptors or 
α5GABAA receptors. We evaluated the antagonists (see Table 1) βCCT (α1GABAA-
preferring, Huang et al., 2000); 3-PBC (α1GABAA-preferring; Harvey et al., 2002); and 
XLi-093 (α5GABAA-selective; Li et al., 2003). When rightward shifts in the triazolam self-
administration dose–effect functions were evident, these results were analyzed using in vivo 
apparent pA2 analysis (Rowlett et al., 2005; Tallarida, 2000; Woods et al., 1992). This 
analysis enabled us to quantitatively analyze the potency of the antagonists and to draw 
conclusions or hypotheses about a role for particular receptor subtypes in the reinforcing 
effects of benzodiazepines.
2. Materials and methods
2.1. Animals
Subjects were 4 male adult rhesus monkeys (Macaca mulatta), individually housed and 
maintained on a 12-h lights-on/12-h lights-off cycle (lights on at 7:00 AM), with water 
available continuously. Monkeys received Teklad monkey diet, supplemented with fruits 
and vegetables, at least 1 h after the end of the daily session, in quantities that allowed them 
to gain no more than 1 kg during the 100+ days of the study. Initial weights were 8–9 kg, 
with no significant changes noted over the course of the experiment. Three of the four 
monkeys had experience self-administering benzodiazepines and/or compounds that bind to 
benzodiazepine sites; the fourth monkey was experimentally naïve. Animals were 
maintained in accordance with the guidelines of the Committee on Animals of Harvard 
Medical School and the Guide for Care and Use of Laboratory Animals (8th edition, 2011). 
Research protocols were approved by the Harvard Medical School Institutional Animal Care 
and Use Committee.
Monkeys were prepared with a chronic indwelling venous catheter (polyvinyl chloride, i.d.: 
0.64 mm; o.d.: 1.35 mm) according to previously described procedures (Platt et al., 2011). 
Monkeys were anesthetized initially with 10–20 mg/kg i.m. of ketamine. Throughout 
surgery, anesthesia was maintained by an isoflurane/oxygen mixture. Under aseptic 
conditions, a catheter was implanted in the femoral, brachial, or jugular vein and passed to 
the level of the right atrium. The distal end of the catheter was passed subcutaneously and 
exited in the mid-scapular region. The external end of the catheter was fed through a fitted 
jacket and tether system (Lomir Biomedical, Toronto, Canada) and attached to a fluid swivel 
mounted to the animal’s cage. The catheters were flushed daily with heparinized saline 
(150–200 U/ml).
2.2. Self-administration
Daily drug self-administration sessions occurred in each monkey’s home cage. Monkeys 
were trained to self-administer the benzodiazepine midazolam (0.03 mg/kg/infusion) under a 
PR schedule of i.v. drug injection (Shinday et al., 2013). At the beginning of each session, a 
set of two white stimulus lights above a response lever was illuminated (Med Associates, St 
Albans, VT). Upon completion of a response requirement, the white lights were 
extinguished and a set of two red stimulus lights were illuminated for 1-s, coinciding with a 
1-s infusion. Each trial ended with either an injection or the expiration of a 30-min limited 
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hold. Trials were separated by a 30-min timeout period, during which all lights were 
extinguished and responding had no programmed consequences.
Experimental sessions consisted of 5 components made up of 4 trials each. The response 
requirement remained constant for each of the 4 trials within a component, and doubled 
during each successive component. The session ended when a monkey self-administered a 
maximum of 20 injections or when the response requirement was not completed for two 
consecutive trials. The PR schedule consisted of a sequence of response requirements: 40, 
80, 160, 320, and 640 responses per injection. Once performance was stable under these 
conditions (no increasing or decreasing trend in the number of injections per session for 
three consecutive sessions), midazolam or saline was made available on alternating days.
Once self-administration was again stable (low levels of responding during saline 
availability and stable self-administration during drug availability), test sessions (T) were 
added to the alternating sequence of midazolam (M) and saline (S) sessions according to the 
following sequence: MTSMTSTMST, etc. During test sessions, a dose of triazolam was 
made available either alone or following a 5-min pretreatment with an i.v. dose of 
benzodiazepine receptor antagonist. After an initial determination of the triazolam dose–
effect function, the antagonists were evaluated in the following order: flumazenil, βCCT, 3-
PBC, XLi-093. Doses of antagonist were evaluated in a balanced order, except that an 
antagonist was finished first prior to moving to the second antagonist. After completing tests 
with flumazenil and βCCT, the dose–effect function for triazolam was re-determined to 
ensure that no changes in triazolam’s potency had occurred.
2.3. Drugs
Triazolam and flumazenil were purchased from Sigma-Aldrich (St. Louis, MO, USA) and 
dissolved in 50% propylene glycol, 50% sterile water. βCCT (β-carboline-3-carboxylate-
tert-butyl ester; Huang et al., 2000; June et al., 2003), 3-PBC (3-propoxy-β-carboline 
hydrochloride; Harvey et al., 2002) and XLi-093 (1,3-bis(8-ethynyl-5,6-dihydro-5-methyl-6-
oxo-4H-imidazo-[1,5a][1,4]benzodiazepine-3-carboxy)propyl diester; Li et al., 2003) were 
synthesized at the Department of Chemistry and Biochemistry at the University of 
Wisconsin–Milwaukee. βCCT, 3-PBC, and XLi-093 were dissolved in 20% ethanol, 60% 
propylene glycol, and 20% sterile water. All doses of triazolam and antagonists were chosen 
based on previous work in our laboratory using rhesus monkeys and the i.v. route of 
administration.
2.4. Data analysis
During day-to-day sessions and testing, the primary dependent measure was the number of 
injections self-administered per session. Differences from vehicle or maximum number of 
injections/session maintained by triazolam were determined by Bonferroni t-tests (alpha 
level constrained to p ≤ 0.05). In order to obtain potency estimates, the self-administration 
data were analyzed as percent of maximum for individual subjects with maxima being the 
highest number of injections/session obtained for an individual monkey with triazolam 
alone. Potency values (dose engendering a 50% maximum effect; ED50) were calculated in 
individual monkeys by log-linear regression when at least three data points were available 
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on the linear portion of the dose–effect curve or by interpolation when only two data points 
(one above and one below 50%) were available. These values were obtained by converting 
the maximum number of injections per session of triazolam alone to 100% for individual 
monkeys. For each monkey, dose ratios were calculated as the ED50 of triazolam in the 
presence of some dose of antagonist divided by the ED50 of triazolam alone.
Dose ratios also were used to calculate in vivo apparent pA2 values and to construct Schild 
plots for flumazenil, 3-PBC, and βCCT antagonism of the reinforcing effects of triazolam. In 
vivo apparent pA2 values were defined as the negative logarithm of the molar dose of 
antagonist required to produce a 2-fold rightward shift in the triazolam dose–effect function, 
and these values provide an in vivo estimate of the affinity of the antagonist for the receptor 
that mediates the effects of triazolam (Rowlett and Woolverton, 1996; Tallarida, 2000; 
Woods et al., 1992). Schild analysis was conducted by plotting the logarithm of the dose 
ratio minus one (log DR − 1) as a function of the dose of the negative logarithm of the molar 
dose of antagonist. Here, the slope of the Schild plot was statistically compared to −1 as an 
evaluation of the assumption of unity (Tallarida, 2000) and to zero as an evaluation of a 
significant relationship between log (DR − 1) and dose of antagonist, in both cases by 
comparing 95% confidence limits (CIs). If slopes were equal to −1.0 but different from zero, 
the regression analysis was repeated with the slope of the regression line set at −1.0 
(constrained method). In theory, this latter approach should improve estimation of pA2 
values, based on the assumption that unity was achieved and slight deviations from −1.0 
were due to random sampling error.
For all three antagonists, the in vitro potency at each GABAA receptor subtype was 
available from experiments with human cloned receptors in HEK cells (Harvey et al., 2002; 
Huang et al., 2000). We compared the potencies of antagonism in self-administration to the 
potencies based on binding affinities obtained in the cloned human GABAA receptor 
subtypes, in order to determine if in vivo apparent pA2 values could accurately predict 
relative potencies among compounds and binding sites. The binding affinities for all 
antagonists in cloned receptors were converted to pKi values. Apparent pA2 (constrained) 
and pKi values were compared using linear regression analysis, with the prediction being 
that the slope for α1GABAA receptor subtypes would be closest to 1.0 relative to the other 
receptor subtypes.
3. Results
3.1. Triazolam self-administration
Under training conditions, presentation of saline engendered low rates of responding in each 
monkey (range = 2–4 injections/session), whereas presentation of midazolam resulted in a 
significantly greater number of injections/session (midazolam range = 13–15 injections/
session), consistent with this drug functioning as a positive reinforcer. When substituted for 
midazolam during test sessions, triazolam alone functioned as a reinforcer, producing dose–
dependent increases in self-administration behavior, with break points (i.e., last response 
requirement completed) of a maximum of 320 responses/injection (data not shown). Doses 
of 0.001 to 0.01 mg/kg/injection maintained mean number of injections/session above 
vehicle levels (Bonferroni t-tests, p < 0.05).
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3.2. Antagonism of triazolam self-administration: Rightward shifts in dose–response 
functions
Fig. 1 shows the self-administration of triazolam alone and following pretreatment with 
flumazenil (left panel), and the α1GABAA receptor-preferring antagonists βCCT (middle 
panel) and 3-PBC (right panel). These data were converted to percent of the maximum effect 
engendered by triazolam in order to calculate ED50 values. For the α5GABAA-selective 
antagonist XLi-093, no antagonism was evident at any of the doses tested (0.3–3.0 mg/kg, 
i.v., N = 3; data not shown). To summarize the results with XLi-093, we have provided the 
ED50 values and dose ratios in Table 2. For all antagonists, it is important to note that self-
administration sessions had the potential to last approximately 9.5 h, i.e., longer than the 
antagonist duration of action. However, the contingency in the PR schedule that the sessions 
end with 2 consecutive limited holds without completing a response requirement limited the 
session duration. Although non-consecutive trials could occur (i.e., a monkey could skip 
trials, which in turn would result in self-administration once the antagonist was eliminated), 
there were no instances during the study in which non-consecutive trials were completed.
In general, flumazenil administration resulted in blockade of triazolam self-administration 
that was overcome by increasing the triazolam dose (Fig. 1, left panel). In most cases, 
increasing the triazolam dose in the presence of flumazenil resulted in a percent maximum 
obtained that was at or near 100% (i.e., surmountable antagonism); and we obtained 4 
rightward shifts in the triazolam dose–response function. Similarly, βCCT administration 
resulted in rightward shifts in the dose–response function consistent with surmountable 
antagonism (Fig. 1, middle panel). As with flumazenil and βCCT, 3-PBC administration 
resulted in surmountable antagonism (Fig. 1, right panel), however, we had only 3 rightward 
shifts in the triazolam dose–response function for all monkeys due to catheter failure in one 
animal.
3.3. In vivo apparent pA2 analyses
Fig. 2 shows Schild plots, either unconstrained (i.e., all variables free to vary in the linear 
regression; top panel) or constrained (i.e., slope constrained to −1.0; bottom panel). Table 3 
shows the results of Schild analyses using the unconstrained and constrained slope 
approaches for the 3 antagonists. The unconstrained slope analysis (shown in the left 
columns of the table) revealed average slopes that ranged from −0.85 to −1.45 and did not 
differ statistically from unity (−1.0) but did differ significantly from zero, based on 95% CIs. 
The average in vivo apparent pA2 values showed a rank order of potency of flumazenil = 
βCCT > 3-PBC (comparison of 95% CIs) based on constrained values.
3.4. Comparison of in vivo and in vitro potencies
The primary purpose for computing apparent pA2 values was to calculate relative potencies 
that, in turn, could be used to compare with relative potencies based on binding affinities 
across GABAA receptor subtypes obtained from cloned human receptors in vitro. As shown 
in Fig. 3, linear relationships were evident for the antagonists across the four binding sites, 
with R2 values that were relatively high (0.78–0.87), though not statistically significant (p’s 
= 0.23–0.31). The lack of statistical significance likely was due to the low sample size (i.e., 
calculations based on 3 antagonists) and therefore preclude strong conclusions regarding a 
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role for any receptor subtype in antagonism of triazolam self-administration. However, we 
hypothesized that the slope for α1GABAA receptors would be 1.0, i.e., a change in 
antagonist binding affinity for α1GABAA sites in vitro predicts the equivalent change in 
antagonist potency in vivo. In contrast to our hypothesis, the predicted slope of 1.0 was 
approached more closely for regressions of antagonist potency with α2GABAA and 
α3GABAA binding affinities (slopes = 0.88 and 0.90, respectively) than for α1GABAA 
binding affinities (slope = 0.48) or α5GABAA binding affinities (slope = 1.50).
4. Discussion
Conventional benzodiazepines bind non-selectively to α1GABAA, α2GABAA, α3GABAA, 
and α5GABAA, receptors, and the role of these different GABAA receptor subtypes in the 
reinforcing effects of benzodiazepines has not been characterized fully. In the present study, 
the conventional benzodiazepine triazolam demonstrated reinforcing effectiveness similar to 
previously-reported findings from our laboratory (e.g., Fischer and Rowlett, 2011), and this 
effect was antagonized by the non-selective benzodiazepine antagonist flumazenil in a dose-
dependent and surmountable fashion. Pretreatments with the α1GABAA receptor-preferring 
antagonists βCCT and 3-PBC also produced predominantly rightward shifts in the triazolam 
dose–effect function. In contrast, the α5GABAA receptor antagonist XLi-093 did not alter 
self-administration of triazolam. Collectively, these data suggest that non-selective and 
α1GABAA-preferring antagonists, but not an α5GABAA-selective antagonist, can block the 
reinforcing effects of a benzodiazepine in a manner consistent with competitive antagonism.
Schild analysis was conducted to determine potencies, as well as in vivo estimates of 
affinity, for the antagonists that blocked the reinforcing effects of triazolam. The slopes for 
the Schild plots for flumazenil, βCCT, and 3-PBC antagonism of triazolam self-
administration were not statistically different from −1. Therefore, apparent pA2 values could 
be calculated, and these affinity estimates indicated a rank order of potency of flumazenil = 
βCCT > 3-PBC, based on comparisons of 95% CIs. To our knowledge, this is the first study 
to determine in vivo affinity estimates for the reinforcing effects of a benzodiazepine 
following antagonist administration, providing an experimental framework for using this 
pharmacological approach to exploring mechanisms of action underlying benzodiazepine 
self-administration.
The observation that the Schild plot slopes for flumazenil, βCCT, and 3-PBC included the 
value −1 suggests that the reinforcing effects of triazolam were mediated by a single 
population of pharmacologically similar receptors. For flumazenil, these pharmacologically 
similar receptors may include the α1GABAA, α2GABAA, α3GABAA and/or α5GABAA 
receptors, as flumazenil is known to bind non-selectively across these GABAA receptor 
subtypes (see Table 1). The finding that the Schild plot slope for flumazenil included −1 is 
in contrast to a previous study which assessed flumazenil antagonism of the discriminative 
stimulus effects of triazolam and in which the slope of the Schild plot was different from 
unity (Lelas et al., 2001, 2002). One possible contributor to this departure from unity is that 
the discriminative stimulus effects of triazolam may involve a receptor population other than 
benzodiazepine-sensitive GABAA receptors. Taken together, these dual findings raise the 
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possibility that the reinforcing properties and discriminative stimulus properties of triazolam 
may be mediated by distinct receptor populations.
Schild analysis also revealed that the slopes for βCCT and 3-PBC did not differ from unity, 
again suggesting that the effects of triazolam were mediated by a single population of 
receptors. As βCCT and 3-PBC are α1GABAA-preferring antagonists, it would be logical to 
assume that the reinforcing properties of triazolam in rhesus monkeys may involve the 
α1GABAA receptor subtype. In support of this conclusion, the rank order of potencies 
calculated from the in vivo apparent pA2 values were most similar to the rank order of 
potencies for the antagonists based on in vitro pKi values at the cloned α1GABAA receptor, 
with flumazenil and βCCT equipotent and 3-PBC significantly less potent. Collectively, 
these findings are suggestive of a role for α1GABAA receptor in the reinforcing effects of 
benzodiazepines, although due to the current lack of availability of α2GABAA and 
α3GABAA receptor-preferring antagonists, we are unable to directly assess α2GABAA and 
α3GABAA receptor involvement in benzodiazepine reinforcement.
To explore the role of GABAA receptor subtypes and the blockade by βCCT and 3-PBC 
further, we calculated pKi values from experiments in which the binding of the 3 antagonists 
to cloned GABAA receptor subtypes was assessed (Huang et al., 2000; Harvey et al., 2002). 
We then regressed the pKi values with the apparent pA2 values obtained from self-
administration. We hypothesized that if the relative potencies were similar across 
antagonists, then the slope closest to 1.0 would be for α1GABAA binding, consistent with 
the statistical comparison of rank order of potency at α1GABAA receptors (flumazenil = 
βCCT > 3-PBC). Interestingly, the opposite was observed. That is, the slopes for α2GABAA 
and α3GABAA binding approached 1.0, whereas for α1GABAA binding the slope was 0.48 
and α5GABAA binding the slope was 1.50. While strong conclusions are precluded because 
of the underpowered regression analyses (and consequent lack of statistical significance), 
these findings raise the possibility that the binding sites that 3-PBC, βCCT and flumazenil 
antagonized were more likely to be the α2-and/or α3GABAA receptor sites than either α1- 
or α5GABAA sites. This possibility is bolstered by our previous work with subtype-
selective agonists, which implicated the α3GABAA, and potentially the α2GABAA, receptor 
subtype in the reinforcing effects of benzodiazepines (Rowlett et al., 2005; Shinday et al., 
2013).
Although our previous studies combined with the present report cast doubt on a sole role for 
α1GABAA receptor subtypes in the reinforcing effects of benzodiazepines, there are other 
lines of evidence that do suggest modulation of benzodiazepine reinforcement by this 
subtype. First, α1GABAA subtype-preferring agonists are self-administered robustly by non-
human primates, often to a degree greater than other benzodiazepine-type drugs (e.g., 
Griffiths et al., 1992; Rowlett et al., 2005; Rowlett and Lelas, 2007). Second, mice with a 
point mutation that rendered the α1GABAA receptor insensitive to benzodiazepines had a 
reduced preference for a benzodiazepine in a two-bottle choice procedure, in contrast to 
wild-type mice (e.g., Engin et al., 2014). Finally, α1GABAA receptors appear to play a key 
role in the self-administration of benzodiazepines in monkeys with a history of cocaine self-
administration (Shinday et al., 2013). Given these observations, the precise role of 
α1GABAA receptors in the reinforcing effects of benzodiazepines remains unclear at 
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present. We have proposed that this subtype can play a modulatory role on reinforcing 
effects of benzodiazepines, even though α1GABAA subtypes may not be necessary for self-
administration per se.
In contrast to the effects observed with flumazenil, βCCT and 3-PBC, the α5GABAA-
selective antagonist XLi-093 did not produce significant shifts in the triazolam dose–effect 
function. The dose range (0.3–3.0 mg/kg, i.v.) for XLi-093 used in the present study was the 
same as used previously, in which this ligand dose-dependently reversed triazolam-induced, 
but not zolpidem-induced, attenuation of performance by rhesus monkeys on a cognitive 
task (Makaron et al., 2013). Because zolpidem does not bind to α5GABAA receptors, the 
results of Makaron et al. (2013) provide support for the idea that XLi-093 has selectivity for 
this receptor subtype over the dose range tested. Therefore, our current findings provide 
evidence that α5GABAA receptors may play a limited role (if any) in the reinforcing 
properties of benzodiazepines. Of all the benzodiazepine-sensitive GABAA receptor 
subtypes, the α5GABAA subtype is one of the more discretely localized anatomically in the 
brain, as it is expressed primarily in hippocampal regions. The hippocampal formation has 
been linked extensively with memory processes and likely plays a role in drug taking (e.g., 
Schwabe et al., 2014); however, our findings suggest that this brain region does not play a 
critical role in benzodiazepine taking, at least under the conditions of this study.
There are alternate possibilities and/or factors that must be considered when interpreting the 
findings in our paper. In particular, although preliminary behavioral work in our laboratories 
suggested that the onset and durations of action among the 3 antagonists are similar, 
pharmacokinetics of the antagonists may have contributed to the differences in relative 
potency. In this regard, differences in CNS penetration and/or metabolism among the 
antagonists could alter in vivo potencies, and this pharmacokinetic information is not 
available at this time for 3-PBC or βCCT in rhesus monkeys.
The findings from the present study demonstrated competitive antagonism of the reinforcing 
effects of triazolam under a PR procedure, confirming a role for GABAA receptors in 
behavior maintained by a conventional benzodiazepine-type drug. However, although βCCT 
and 3-PBC have selectivity for α1GABAA receptor subtypes, our findings do not provide 
robust evidence for antagonism via this subtype. Instead, these results point to α2GABAA 
and/or α3GABAA receptors being critically involved in antagonism of triazolam’s effects, 
based on relative potencies of the antagonists. Taken together with our previous findings 
(Rowlett et al., 2005; Shinday et al., 2013), the reinforcing effects of benzodiazepines may 
involve α3GABAA receptors specifically, since the α3GABAA-prefering agonist TP003 was 
self-administered, although α2GABAA receptors also have been implicated in a recent study 
using transgenic mouse technology (Engin et al., 2014). Finally, our results suggest that 
α5GABAA receptors play little-to-no role in benzodiazepine reinforcement. These 
hypotheses should provide an important framework for studying the role of different 
GABAA receptor subtypes in the behavioral effects of benzodiazepine-type drugs, which in 
turn should help guide development of improved therapeutic agents for treating anxiety-
related disorders.
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Fig. 1. 
Blockade of triazolam self-administration by the non-selective benzodiazepine site 
antagonist flumazenil and the α1GABAA subtype-preferring antagonists βCCT and 3-PBC 
under a progressive-ratio schedule of i.v. midazolam self-administration. Data are expressed 
as the average percent of maximum (±SEM), with maxima being the highest number of 
injections/session obtained for an individual monkey for triazolam alone (N = 4 per 
antagonist). Doses for each antagonist (administered i.v., 5-min pre-session) are shown in 
the figure legends. Note that the same triazolam dose–effect function was used for 
flumazenil and βCCT and was re-determined for 3-PBC.
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Fig. 2. 
In vivo apparent pA2 analyses of antagonism of the reinforcing effects of triazolam in rhesus 
monkeys (N = 4) trained under a progressive-ratio schedule of i.v. midazolam injection. Top 
panel: Schild plots for the 3 antagonists with Schild regressions calculated under conditions 
in which all parameters were free to vary (i.e., “unconstrained”). Bottom panel: Schild plots 
in which the parameter of slope of the regression was set at −1.0 (i.e., “constrained”).
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Fig. 3. 
Linear regression analyses of pKi values for 3-PBC, βCCT, and flumazenil for GABAA 
receptors containing α1, α2, α3, and α5 subunits, as a function of in vivo apparent pA2 
values obtained from self-administration studies. Numbers in italics represent the slopes of 
the indicated functions. Small-case letters represent the individual symbols associated with a 
particular antagonist. Data are from n = 4 monkeys (pA2) or previously published data with 
cloned human receptor subtypes (pKi; Huang et al., 2000; Harvey et al., 2002).
Fischer et al. Page 16
Drug Alcohol Depend. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fischer et al. Page 17
Ta
bl
e 
1
B
en
zo
di
az
ep
in
e 
sit
e 
an
ta
go
ni
sts
 u
se
d 
in
 th
e 
pr
es
en
t s
tu
dy
.
Su
bt
yp
e
K i
 
(n
M
)
pK
i (−
log
 K
i [i
n M
])
Li
ga
nd
St
ru
ct
ur
e
α1
α2
α3
α5
α1
α2
α3
α5
Fl
um
az
en
il
0.
79
0.
89
1.
05
0.
60
9.
10
9.
05
8.
98
9.
22
βC
CT
0.
72
15
19
11
1
9.
14
7.
82
7.
72
6.
96
3-
PB
C
5.
2
52
69
58
9
8.
28
7.
28
7.
16
6.
23
Drug Alcohol Depend. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fischer et al. Page 18
Su
bt
yp
e
K i
 
(n
M
)
pK
i (−
log
 K
i [i
n M
])
Li
ga
nd
St
ru
ct
ur
e
α1
α2
α3
α5
α1
α2
α3
α5
X
Li
-0
93
>
10
00
>
10
00
85
8
15
–
–
6.
07
7.
82
A F
ro
m
 H
ar
ve
y 
et
 a
l. 
(20
02
), H
ua
ng
 e
t a
l. 
(20
00
), L
i e
t a
l. 
(20
03
).
Drug Alcohol Depend. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fischer et al. Page 19
Table 2
Potency values (ED50) and dose ratios of triazolam alone and following pretreatment with the α5GABAA-
selective antagonist, XLi-093.
Antagonist dose
(mg/kg, i.v.)
N ED50 (SEM) Dose ratio (SEM)
0 3 0.00046 (0.00027) –
0.1 3 0.00047 (0.00018) 1.34 (0.27)
0.3 3 0.00058 (0.00023) 1.64 (0.48)
1.0 3 0.00047 (0.00027) 1.07 (0.31)
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Table 3
In vivo apparent pA2 analyses of antagonism of the reinforcing effects of triazolam.
Schild analyses, unconstrained slopeA Schild analyses, constrained slopeB
Antagonist pA2 (95% CIs) Slope (95% CIs) pA2 (95% CIs) Slope (95% CIs)
Flumazenil 7.24 (6.91, 8.51) − 1.32 (−2.16, −0.48) 7.40 (7.18, 7.75) − 1.0
βCCT 6.51 (6.01, 7.43) − 1.45 (−2.47, −0.40) 6.80 (6.31, 7.29) − 1.0
3-PBC 5.61 (5.18, 5.70) − 0.85 (−1.61, −0.09) 5.55 (5.30, 5.71) − 1.0
A
Individual data points for the antagonists were averaged for each monkey and Schild regression conducted on the grouped data. For the regression 
analysis, all parameters were free to vary.
B
Individual data points for the antagonists were averaged for each monkey and Schild regression conducted on the grouped data. For the regression 
analysis, the slope values were constrained to −1.0.
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